{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:47:54Z","timestamp":1790221674572,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.rmed.2017.07.013","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T12:30:47Z","timestamp":1500467447000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-3806","authenticated-orcid":false,"given":"Danilo","family":"Di Bona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Frisenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Minenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pasculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kourtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Simona","family":"Rucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Nico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Albanesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Giliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"D'Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2017.07.013_bib2","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.rmed.2017.07.013_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.rmed.2017.07.013_bib4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2017.07.013_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.rmed.2017.07.013_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2017.07.013_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin. Exp. Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2017.07.013_bib8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/all.12815","article-title":"'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2017.07.013_bib9","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.07.013_bib10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.rmed.2010.04.013","article-title":"Italian real-life experience of omalizumab","volume":"104","author":"Cazzola","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.07.013_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/02770903.2011.637598","article-title":"Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel","volume":"49","author":"Rottem","year":"2012","journal-title":"J.\u00a0Asthma"},{"key":"10.1016\/j.rmed.2017.07.013_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3109\/02770903.2012.668255","article-title":"Spanish Registry. Omalizumab therapy in severe asthma: experience from the Spanish registry - some new approaches","volume":"49","author":"Vennera Mdel","year":"2012","journal-title":"J.\u00a0Asthma"},{"key":"10.1016\/j.rmed.2017.07.013_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.aller.2012.07.006","article-title":"Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal","volume":"42","author":"Vieira","year":"2014","journal-title":"Allergol. Immunopathol."},{"key":"10.1016\/j.rmed.2017.07.013_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.rppneu.2013.07.006","article-title":"Clinical experience with Omalizumab in a Portuguese severe asthma unit","volume":"20","author":"Alfarroba","year":"2014","journal-title":"Rev. Port. Pneumol."},{"key":"10.1016\/j.rmed.2017.07.013_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02770903.2013.790419","article-title":"Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study","volume":"50","author":"Barnes","year":"2013","journal-title":"J.\u00a0Asthma"},{"key":"10.1016\/j.rmed.2017.07.013_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1710-1492-9-47","article-title":"Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting","volume":"9","author":"Braunstahl","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.rmed.2017.07.013_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1378\/chest.12-1372","article-title":"Does omalizumab make a difference to the real life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma","volume":"143","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.07.013_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pupt.2014.09.007","article-title":"Xolair Italian Study Group. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy","volume":"31","author":"Novelli","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2017.07.013_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pupt.2011.11.004","article-title":"Long-term omalizumab treatment in severe allergic asthma: the south-eastern Mediterranean \u201creal-life\u201d experience","volume":"25","author":"Tzortzaki","year":"2012","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2017.07.013_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.aller.2013.11.008","article-title":"Real life study of three years omalizumab in patients with difficult-to-control asthma","volume":"43","author":"Tiro","year":"2015","journal-title":"Allergol. Immunopathol."},{"key":"10.1016\/j.rmed.2017.07.013_bib21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study of moderate-to-severe asthma","volume":"139","author":"Iribarren","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2017.07.013_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2017.07.013_bib23","unstructured":"European medicines agency EMEA\/493707\/2009 Xolair. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000606\/WC500057293.pdf."},{"key":"10.1016\/j.rmed.2017.07.013_bib24","series-title":"R: a Language and Environment for Statistical Computing","author":"R Core Team","year":"2016"},{"issue":"2","key":"10.1016\/j.rmed.2017.07.013_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2017.07.013_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","volume":"120","author":"Cox","year":"2007","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2017.07.013_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents-updated diagnosis, management and treatment","volume":"3","author":"Galv\u00e3o","year":"2015","journal-title":"J.\u00a0Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2017.07.013_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1081-1206(10)60194-9","article-title":"The safety of omalizumab therapy in a patient with severe persistent allergic asthma and hepatitis C","volume":"103","author":"Antonicelli","year":"2009","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2017.07.013_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/jdv.12450","article-title":"Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C","volume":"29","author":"Leiva-Salinas","year":"2015","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.rmed.2017.07.013_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2017.07.013_bib31","unstructured":"Xolair (omalizumab) prescribing information. Available at: https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf [Accessed 28.02.17]."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117302111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117302111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:36:40Z","timestamp":1760614600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117302111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"alternative-id":["S0954611117302111"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.07.013","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}